Pfizer (PFE) valuation

Run six valuation models on Pfizer with live data: DCF, Reverse DCF, Graham number, Monte Carlo, scenarios and sum-of-the-parts (NAV).

PFE
PFE

Pfizer

PFE · Healthcare

Current price

28,53 USD

𝕏 Share on X
You're trying every model for free, no account needed. Sign up to save your analyses →

Valuation

Market cap
162.59 B USD
PE (TTM | NTM | +1y)
40.75 | 9.66 | 9.66
Price / Sales
2.56
EV / EBITDA
8.58
Price / Book
1.83

Cash flow

FCF yield(2.28 / 28.52)
+8%
SBC-adjusted FCF yield
—
SBC impact
—

Margins & growth

Profit margin
+6.34%
Operating margin
+29.07%
Quarterly earnings (YoY)
—
Quarterly revenue (YoY)
—

Balance

Cash
14.28 B USD
Debt
63.41 B USD
Net position
-49.13 B USD

Dividend

Dividend yield
+5.96%
Payout ratio
+245.71%
Next payout
12/7/2026

Price (5 years)

-43.81%
59.48 USD

What the market paid for its earnings

P/E (TTM)40.8×
255075Its own median 17.0×Its own mean 21.1×20212026

Each week's price divided by the earnings per share already reported by that date — four quarters where a company reports them, its last full year otherwise. Loss-making weeks are not drawn. Both lines are the company's own: the median is where it traded in half its weeks, the mean is where the extremes pull that average to. A mean well above the median means the high ratings were occasional rather than usual.

What the market paid for the year ahead

Forward P/E9.7×
050100150Its own median 20.6×Its own mean 43.2×20212026

Each week's price divided by the earnings of the year still ahead of it. Those years have since happened, so this is the multiple paid against the figure that landed: nobody records what analysts expected at the time. The most recent stretch uses today's consensus. Both lines are the company's own: the median is where it traded in half its weeks, the mean is where the extremes pull that average to. A mean well above the median means the high ratings were occasional rather than usual.

What analysts expect

Consensus revenue and earnings per share for the periods not yet reported.

Revenue forecast

ReportedEstimate
05B10B15BQ4 25: 17.56 B USDQ4 25Q1 26: 14.45 B USDQ1 26Q2 26: 15.03 B USDQ2 26Q3 26: 16.58 B USDQ3 26Q4 26 · Estimate: 17.22 B USD (16.62 B USD – 17.91 B USD)Q4 26Q1 27 · Estimate: 14.12 B USD (13.80 B USD – 14.40 B USD)Q1 27USD

Consensus of 16 analysts for Q4 26 · -1.91% year on year

EPS forecast

ReportedEstimate
00.250.50.75Q4 25: 0.66 · expected 0.57 (+16.18%)Q4 25Q1 26: 0.75 · expected 0.72 (+3.93%)Q1 26Q2 26: 0.77 · expected 0.68 (+12.87%)Q2 26Q3 26: 0.87 · expected 0.74 (+18.26%)Q3 26Q4 26 · Estimate: 0.68 (0.63 – 0.83)Q4 26Q1 27 · Estimate: 0.70 (0.56 – 0.77)Q1 27

Consensus of 18 analysts for Q4 26 · +3.79% year on year · adjusted earnings

Analyst consensus from Yahoo Finance. The dashed bar is the average and the whisker runs from the lowest analyst to the highest. On periods already reported, the green or red line marks what had been expected: below the bar means the company beat it. EPS is measured on an adjusted basis, which is what analysts forecast against and is not the accounting profit in the statements.

Revenue

estimate
05B10B15BQ4 23: 13.49 B USDQ4 23Q4 23: 5.93 B USDQ1 24: 14.88 B USDQ1 24Q2 24: 13.28 B USDQ3 24: 17.70 B USDQ3 24Q1 25: 13.72 B USDQ3 25: 16.65 B USDQ3 25Q4 25: 17.56 B USDQ1 26: 14.45 B USDQ1 26Q2 26: 15.03 B USDQ3 26: 16.58 B USDQ3 26Q4 26 · estimate: 17.22 B USDQ4 26USD

EBITDA

03B5BQ4 23: -1.09 B USDQ4 23Q4 23: -1.81 B USDQ1 24: 5.93 B USDQ1 24Q2 24: 2.42 B USDQ3 24: 7.24 B USDQ3 24Q1 25: 5.05 B USDQ3 25: 5.65 B USDQ3 25Q4 25: 756.00 M USDQ1 26: 5.45 B USDQ1 26Q2 26: 1.64 B USDQ3 26: 5.62 B USDQ3 26USD

Net income

-2B02B4BQ4 23: -2.38 B USDQ4 23Q4 23: -3.37 B USDQ1 24: 3.12 B USDQ1 24Q2 24: 41.00 M USDQ3 24: 4.47 B USDQ3 24Q1 25: 2.97 B USDQ3 25: 3.54 B USDQ3 25Q4 25: -1.65 B USDQ1 26: 2.69 B USDQ1 26Q2 26: -248.00 M USDQ3 26: 3.24 B USDQ3 26USD

Free cash flow

03B5BQ4 23: 2.65 B USDQ4 23Q4 23: 4.20 B USDQ1 24: 386.00 M USDQ1 24Q2 24: -2.42 B USDQ3 24: 6.06 B USDQ3 24Q1 25: 1.77 B USDQ3 25: 4.00 B USDQ3 25Q4 25: 4.50 B USDQ1 26: 2.18 B USDQ1 26Q2 26: 302.00 M USDQ3 26: 4.80 B USDQ3 26USD

EPS

-0.500.5Q4 23: -0.42Q4 23Q4 23: -0.59Q1 24: 0.55Q1 24Q2 24: 0.01Q3 24: 0.78Q3 24Q1 25: 0.52Q3 25: 0.62Q3 25Q4 25: -0.29Q1 26: 0.47Q1 26Q2 26: -0.04Q3 26: 0.56Q3 26

Cash & debt

CashDebt
020B40B60BQ4 23 · Cash: 3.15 B USDQ4 23Q4 23 · Cash: 2.85 B USDQ1 24 · Cash: 719.00 M USDQ1 24Q2 24 · Cash: 1.05 B USDQ3 24 · Cash: 1.09 B USDQ3 24Q1 25 · Cash: 1.43 B USDQ3 25 · Cash: 1.34 B USDQ3 25 · Debt: 60.85 B USDQ3 25Q4 25 · Cash: 1.14 B USDQ4 25 · Debt: 63.96 B USDQ1 26 · Cash: 1.70 B USDQ1 26 · Debt: 63.73 B USDQ1 26Q2 26 · Cash: 976.00 M USDQ2 26 · Debt: 63.19 B USDQ3 26 · Cash: 1.82 B USDQ3 26 · Debt: 62.67 B USDQ3 26USD

Return of capital

DividendsBuybacks
01B2BQ4 23 · Buybacks: 0.00 USDQ4 23Q4 23 · Buybacks: 0.00 USDQ3 25 · Dividends: 2.44 B USDQ3 25Q4 25 · Dividends: 2.45 B USDQ1 26 · Dividends: 2.45 B USDQ1 26Q2 26 · Dividends: 2.45 B USDQ3 26 · Dividends: 2.45 B USDQ3 26USD

Stock-based compensation

0100M200M300MQ4 23: 151.00 M USDQ4 23Q4 23: 121.00 M USDQ1 24: 220.00 M USDQ1 24Q2 24: 206.00 M USDQ3 24: 274.00 M USDQ3 24Q1 25: 170.00 M USDQ3 25: 201.00 M USDQ3 25Q4 25: 225.00 M USDQ1 26: 272.00 M USDQ1 26Q2 26: 249.00 M USDQ3 26: 362.00 M USDQ3 26USD

Operating expenses

R&DSG&A
02B4B6BQ4 23 · SG&A: 3.28 B USDQ4 23Q4 23 · SG&A: 4.58 B USDQ1 24 · SG&A: 3.50 B USDQ1 24Q2 24 · SG&A: 3.72 B USDQ3 24 · SG&A: 3.24 B USDQ3 24Q1 25 · SG&A: 3.03 B USDQ3 25 · R&D: 2.55 B USDQ3 25 · SG&A: 3.19 B USDQ3 25Q4 25 · R&D: 3.21 B USDQ4 25 · SG&A: 4.16 B USDQ1 26 · R&D: 2.49 B USDQ1 26 · SG&A: 2.96 B USDQ1 26Q2 26 · R&D: 2.81 B USDQ2 26 · SG&A: 3.41 B USDQ3 26 · R&D: 3.02 B USDQ3 26 · SG&A: 3.28 B USDQ3 26USD

Source: Yahoo Finance. Quarterly history grows automatically over time as new quarters are published.

Other comparisons

Popular companies